People · Operator
Named in public records as an officer, director or promoter · active 2013–2014 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aminex Therapeutics, Inc. | — | Biotechnology | Series B | $34.5M | $221.7M | 2014 |
| MQT Holdings, LLC | — | Pharmaceuticals | Pre-Seed | $250K | $11.8M | 2013 |
John Rosling at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Rosling on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeffrey Miller | 1 | 9 |
| Jeff Miller | 1 | 4 |
| Thomas Graham | 1 | 3 |
| Roger Ulrich | 1 | 2 |
| Rhonda Rhyne | 1 | 2 |
| David Meeks | 1 | 1 |
| Don Dyer | 1 | 1 |
| Larry Richards | 1 | 1 |
| Stacy Hock | 1 | 1 |
| Joe Piper | 1 | 1 |
| Tane Williams | 1 | 1 |
| Mark Burns | 1 | 1 |
| Donald Mowat | 1 | 1 |
| James Skaggs | 1 | 1 |
| Deyaa Adib | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.